US Patent

US8461179 — Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

Composition of Matter · Assigned to Deciphera Pharmaceuticals LLC · Expires 2034-05-15 · 8y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects dihydronaphthyridines and related compounds as kinase inhibitors for treating or preventing proliferative diseases.

USPTO Abstract

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.

Drugs covered by this patent

Patent Metadata

Patent number: US8461179
Jurisdiction: US
Classification: Composition of Matter
Expires: 2034-05-15
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Deciphera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.